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Abstract: The present study describes the role of the ubiquitin ligase Siah-2 and corepressor N-CoR in controlling 
androgen receptor (AR) and estrogen receptors (ERα and ERβ) signaling in an appropriate animal model (Fischer 
344 female rats) of non-muscle invasive bladder cancer (NMIBC), especially under conditions of anti-androgen 
therapy with flutamide. Furthermore, this study describes the mechanisms of a promising therapeutic alternative 
for NMIBC based on Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride (P-MAPA) 
intravesical immunotherapy combined with flutamide, involving the interaction among steroid hormone receptors, 
their regulators and Toll-like receptors (TLRs). Our results demonstrated that increased Siah-2 and AR protein levels 
and decreased N-CoR, cytochrome P450 (CYP450) and estrogen receptors levels played a critical role in the uro-
thelial carcinogenesis, probably leading to escape of urothelial cancer cells from immune system attack. P-MAPA 
immunotherapy led to distinct activation of innate immune system TLRs 2 and 4-mediated, resulting in increase 
of interferon signaling pathway, which was more effective in recovering the immunosuppressive tumor immune mi-
croenvironment and in recovering the bladder histology features than BCG (Bacillus Calmette-Guerin) treatments. 
The AR blockade therapy was important in the modulating of downstream molecules of TLR2 and TLR4 signaling 
pathway, decreasing the inflammatory cytokines signaling and enhancing the interferon signaling pathway when 
associated with P-MAPA. Taken together, the data obtained suggest that interferon signaling pathway activation 
and targeting AR and Siah-2 signals by P-MAPA intravesical immunotherapy alone and/ or in combination with AR 
blockade may provide novel therapeutic approaches for NMIBC.
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tor, estrogen receptor
Introduction
Bladder cancer (BC) is the second most com-
mon genitourinary malignancy and leads to 
considerable morbidity and mortality worldwide 
[1, 2]. In 2013, 10.510 men and 4.370 women 
died from BC in the USA, representing 18.9% 
and 24.4% of cases, respectively [3]. More than 
70% of BC is superficial; however, 50% of non-
muscle invasive bladder cancers (NMIBC) 
return within 4 years of treatment, and 11% 
progress to an invasive phenotype [4]. NMIBC 
is classified into 3 stages: pTis (flat carcinoma 
in situ), pTa (papillary carcinoma in situ) and pT1 
(tumor invading mucosa or submucosa of the 
bladder wall) [5].
Estrogen receptors (ER), subtypes ERα and 
ERβ, have been implicated in bladder carcino-
genesis because these receptors act as ligand-
activated transcription factors [6, 7]. Although 
both ERα and ERβ have been identified in 
human bladder cells, ERβ is the predominant 
ER type [7, 8]. Some studies suggest a protec-
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tive role of estrogens against prostate, breast 
and ovarian carcinogenesis [7, 9]. However, in 
BC, the expression of ERs and their co-regula-
tors, including p300 and the nuclear receptor 
corepressor (N-CoR), has not been studied. 
N-CoR is a 270-kDa protein that contains dis-
tinct functional domains responsible for inter-
action with nuclear receptors and activation of 
de-acetyltransferase proteins, ultimately result-
ing in targeted repression of transcription [7, 
10]. In the absence of a ligand, N-CoR binds to 
ER and mediates the transcriptional repression 
of ER target genes [7]. 
Previous investigators have shown that signal-
ing mediated by androgen and its receptor 
(androgen receptor-AR) plays an important role 
in the genesis and development of BC, which 
may explain some of the differences between 
tumors in males and females [11]. Additionally, 
this observation may indicate a potential thera-
peutic target [12]. AR expression was verified in 
both normal bladder epithelium and bladder 
carcinomas from male and female patients 
[13]. However, AR expression and the exact 
functional mechanism of androgen/androgen 
receptor signaling in BC development have 
remained unclear to date. One important inter-
action of AR is with the ubiquitin/proteasome 
pathway, which regulated AR stability [14]. The 
ubiquitin/proteasome pathway consists of 
ubiquitin ligases that control the specificity and 
rate of protein degradation. The protein degra-
dation occurs in the proteasome and requires 
three types of enzyme: ubiquitin-activating 
enzymes (E1), ubiquitin-conjugating enzymes 
(E2) and ubiquitin ligases (E3), which catalyze 
the binding of the small protein ubiquitin to 
lysines on a protein target by forming complex-
es with ubiquitin-conjugating enzymes, result-
ing in the directing of modified protein to the 
proteasome for degradation [14]. The Siah 
(seven in absentia homolog) proteins regulate 
ubiquitination-dependent degradation of multi-
ple substrates, including N-CoR, β-catenin, 
TRAF2 and α-ketoglutarate dehydrogenase, 
resulting in resistance to apoptosis and affect-
ing on mitochondrial function [15, 16]. 
Bacillus Calmette-Guerin (BCG) is considered 
the gold standard for the first line treatment of 
high grade flat carcinoma in situ and is used as 
prophylaxis and in the treatment of papillary 
carcinoma in situ (high grade) and tumor invad-
ing mucosa or submucosa of the bladder wall 
[17]. BCG evokes a complex and robust system-
ic immune response, comprising CD4+ T cells 
stimulation and inducing T helper type (Th) 1 
immune response [18]. BCG antigens exerts a 
direct effect cell surfaces of urothelial, leading 
to a massive immune response characterized 
by the induction of cytokine and an influx of 
inflammatory cells into the bladder wall [18, 
19]. In addition, many studies have demon-
strated an important antiproliferative effect of 
BCG on urothelial tumor cells [20, 21]. However, 
undesirable side events related with BCG ther-
apy are observed up to 90% of patients and 
range from cystitis and irritative voiding symp-
toms to major complications such as sepsis 
and death related to the treatment [22, 23]. 
Based on this background, compounds that 
activate the immune system, including vac-
cines, biological response modifiers and tumor 
environment modulators of steroid hormones, 
can be considered potential candidates for the 
development of new treatments of NMIBC aim-
ing to obtain greater therapeutic effect com-
bined with lower toxicity. In this context, toll-like 
receptors (TLRs) agonist compounds may rep-
resent a potential antitumor therapeutic 
approach, because TLRs are implicated in the 
pathogenesis of some tumors, including NMIBC 
[24]. TLRs are key elements of the innate 
immune system, and their signaling pathways 
consist of two pathways: the MyD88 (myeloid 
differentiation primary response 88)-depen-
dent and MyD88-independent (or TRIF-
dependent) pathways [25]. The MyD88-
dependent pathway is common to all TLRs and 
activates NF-kB, resulting in the induction of 
inflammatory chemokines such as Tumor 
Necrosis Factor α (TNF-α) and interleukin-6 (IL-
6). Conversely, the MyD88-independent path-
way is peculiar to the TLR3 and TLR4 signaling 
pathways and activates Interferon (IFN) and 
Interferon Regulatory Factor 3 (IRF-3) [25]. 
As cited, immunotherapy using compounds 
that act as TLR agonists could be a valuable 
approach for the treatment of cancer, whether 
used alone or in combination with existing ther-
apies. In this context, P-MAPA (developed by 
Farmabrasilis, a nonprofit research network) 
has emerged as a potential candidate for intra-
vesical therapy for NMIBC. P-MAPA is a biologi-
cal response modifier obtained by fermentation 
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from Aspergillus oryzae that demonstrates 
important antitumor effect in several animal 
models of cancer, including NMIBC [26, 27]. 
Recent advances of our research group in the 
understanding of its mechanism of action dem-
onstrated that P-MAPA modulates TLR 2 and 4 
in both infectious diseases and cancer [26, 
27].
Here, we describe the role of the Siah-2 ubiqui-
tin ligase and its corepressor N-CoR in control-
ling AR, ERα and ERβ signaling in an appropri-
ate animal model of NMIBC, in particular under 
conditions of anti-androgen therapy with flu-
tamide. Furthermore, we describe the possible 
mechanisms of a promising therapeutic alter-
native for NMIBC based on P-MAPA intravesical 
immunotherapy combined with flutamide, a 
strategy that involves the interaction of steroid 
hormone receptors and their regulators, Siah2 
and N-CoR, with immune system receptors. 
BCG immunotherapy was used as positive con-
trol in this animal model of NMIBC.
Methods
Experimental proceedings
In this study it was used 35 female rats Fischer 
344 strain, aged 7 weeks, weighing on average 
150 grams, obtained from the University of 
Campinas (CEMIB/UNICAMP). For the experi-
ments the protocol followed strictly the ethical 
principles in animal research (CEUA/IB/ 
UNICAMP-protocol number: 3339-1). For the 
induction of NMIBC, 30 female rats were anes-
thetized with both 60 mg/Kg dose of ketamine 
10% (Vibra® Roseira, São Paulo, Brazil) and 5 
mg/Kg dose of xylazine 2% (Vibra® Roseira, 
São Paulo, Brazil) intraperitoneally (i.p.), and 
maintained in this state for 45 min to prevent 
spontaneous micturition. After, these animals 
received 1.5 mg/kg dose of n-methyl-n-nitro-
sourea (MNU; Sigma Chemical Co., St. Louis, 
MO, USA) dissolved in 0.30 mL of sodium 
citrate (1 M pH 6.0) intravesically (i.v.), via a 
22-gauge angiocatheter, every other week for 8 
weeks [27]. The other 5 animals (Control group) 
received a 0.30 mL dose of 0.9% physiological 
saline i.v. every other week for 8 weeks [27]. 
Two weeks after the last dose of MNU, all ani-
mals were submitted to cystography to evalu-
ate the occurrence of tumor and divided into 7 
groups (5 animals per group). The control group 
(Group 1) received a 0.3 mL dose of 0.9% physi-
ological saline intravesically every other week 
for 6 weeks. The MNU group (Non-Muscle 
Invasive Bladder Cancer; Group 2) received the 
same treatment as Group 1. The MNU-BCG 
group (Group 3) received a 106 CFU (40 mg) 
dose of BCG intravesically every other week for 
6 weeks. The MNU-P-MAPA group (Group 4) 
received 5 mg/kg dose of P-MAPA (Far- 
mabrasilis, Campinas, SP, Brazil) intravesically 
every other week for 6 weeks. The MNU-
flutamide group (Group 5) received a 10 mg/kg 
dose of flutamide (Sigma Chemical Co., St. 
Louis, USA) subcutaneously every other day for 
6 weeks for blockade of the androgen receptor. 
The MNU-BCG-flutamide group (Group 6) 
received the same treatment as the Groups 3 
and 5. The MNU-P-MAPA-flutamide group 
(Group 7) received the same treatment as 
Groups 4 and 5. 
After 16 weeks of treatment, the animals were 
euthanized, and their urinary bladders were col-
lected and processed for histopathological, 
immunological and Western Blotting analysis. 
Histopathological analysis
Fragments of the urinary bladders were collect-
ed from 5 animals in each group and fixed in 
Bouin’s solution for 12 hours. After fixation, the 
fragments were washed in 70% ethanol, fol-
lowed by dehydration in an ascending series of 
alcohols. Subsequently, the fragments were 
diaphanized in xylene for 2 hours and embed-
ded in plastic polymer (Paraplast Plus, ST. 
Louis, MO, USA). Then, the specimens were cut 
on a rotary microtome Leica RM 2165 (Leica, 
Munich, Germany) with a thickness of 5 μm, 
stained with hematoxylin-eosin and photo-
graphed with a Zeiss Axiophot (Zeiss, Hamburg, 
Germany) photomicroscope. The urinary blad-
der lesions were diagnosed according to World 
Health Organization/International Society of 
Urological Pathology [5] by a senior 
uropathologist.
Immunodetection of Siah-2 and N-CoR 
Fragments of the urinary bladders were collect-
ed from 5 animals in each group, the same 
used for histopathological analysis, were cut 6 
µm thick sections for immunological analysis. 
The antigens were retrieved in microwave oven 
by boiling the sections in a 10 mM citrate buf-
fer. After that, the sections were incubated in 
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0.3% H2O2 for 15 minutes to block endogenous 
peroxidase. Nonspecific binding was blocked 
by incubating the sections in a blocking solu-
tion for 1 hour at room temperature. Primary 
goat polyclonal antibody sc-5507 (N-14) (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) 
specific for Siah-2 and goat polyclonal sc-1611 
(N-19) (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) specific for N-CoR were diluted 
in 1% BSA and applied to the sections overnight 
at 4ºC. Bound antibody was detected with an 
AdvanceTM HRP kit (Dako Cytomation Inc., USA). 
Secondary labeled polymer (AdvanceTM HRP kit) 
was applied for 40 min at room temperature. 
Peroxidase activity was detected using a diami-
nobenzidine chromogen mixture (AdvanceTM 
HRP kit). Sections were lightly counterstained 
with Harris’ hematoxylin and photographed 
with a Zeiss Axiophot (Zeiss, Hamburg, 
Germany) photomicroscope. 
To evaluate the intensity of antigen immunore-
activity, the percentage of positive-staining uro-
thelial cells and/or lamina propria and muscu-
laris layers cells was examined in ten fields for 
each antibody under high magnification (400×). 
The staining intensity was graded on a scale of 
0-3, and expressed as 0 (no immunoreactivity), 
0% positive urothelial cells; 1(weak immunore-
activity), 1-35% positive urothelial cells; 2 (mod-
erate immunoreactivity), 36-70% positive uro-
thelial cells; 3 (intense immunoreactivity), > 
70% positive urothelial cells [21]. 
Western blotting analysis
Fragments of the urinary bladders were collect-
ed from 5 animals in each group, frozen in liq-
uid nitrogen, weighed and homogenized in 50 
μl/mg of RIPA lysis buffer (EMD Millipore 
Corporation, Billerica, MA, USA). The tissue 
homogenates were centrifuged, and a sample 
of each extract was used for protein quantifica-
tion by Bradford’s method. Aliquots containing 
70 μg of protein were separated by SDS-PAGE 
on 10% or 12% polyacrylamide gels under 
reducing conditions. After electrophoresis, the 
proteins were transferred to Hybond-ECL nitro-
cellulose membranes (Amersham, Pharmacia 
Biotech, Arlington Heights, IL., USA). The mem-
branes were blocked with TBS-T containing 1% 
BSA (bovine serum albumin) and incubated at 
4°C overnight with primary rabbit polyclonal 
antibody 251110 (Abbiotec, San Diego, CA, 
USA) specific for TLR2, rabbit polyclonal 
ab2064 (Abcam, Cambridge, MA, USA) specific 
for MyD88, rabbit polyclonal ab7970 (Abcam, 
Cambridge, MA, USA) specific for NF-kB, rabbit 
polyclonal ab6671 (Abcam, Cambridge, MA, 
USA) specific for TNF-α, rabbit polyclonal anti-
body 251111 (Abbiotec, San Diego, CA, USA) 
specific for TLR4, rabbit polyclonal ab13810 
(Abcam, Cambridge, MA, USA) specific for TRIF, 
rabbit polyclonal ab25950 (Abcam, Cambridge, 
MA, USA) specific for IRF3, mouse monoclonal 
507802 (Biolegend, San Diego, CA, USA) spe-
cific for IFN-γ, rabbit polyclonal sc-816 (N-20) 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA) specific for AR, rabbit monoclonal 04-227 
(E115) (EMD Millipore Corporation, Billerica, 
MA, USA) specific for ERα, rabbit polyclonal 
06-629 (EMD Millipore Corporation, Billerica, 
MA, USA) specific for ERβ, goat polyclonal 
sc-5507 (N-14) (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA) specific for Siah-2, goat 
polyclonal sc-1611 (N-19) (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) spe-
cific for N-CoR and rabbit polyclonal NBP1-
19551 (Novus Biologicals, Littleton, CO, USA) 
specific for Cytochrome P450 (CYP50) diluted 
in 1% BSA. The membranes were then incubat-
ed for 2 h with rabbit or mouse secondary HRP-
conjugated antibodies (diluted 1:3,000 in 1% 
BSA; Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA). Peroxidase activity was detect-
ed by incubation with a diaminobenzidine chro-
mogen (Sigma Chemical Co., St Louis, USA). 
Western blots were run in duplicate, and uri-
nary bladder samples were pooled from 5 ani-
mals per group for each repetition. The semi-
quantitative densitometry (IOD-Integrated Op- 
tical Density) analysis of bands was conducted 
using NIH ImageJ 1.47v software (National 
Institute of Health, USA. Available in: http://rsb.
info.nih.gov/ij/), followed by statistical analy-
sis. β-actin was used as endogenous positive 
controls for standardization of the readings of 
band staining intensity. The results were 
expressed as the mean ± standard deviation of 
the ratio of each band’s intensity to β-actin 
band intensity.
Statistical analysis
For the statistical analysis, analysis of variance 
(ANOVA) was used followed by Tukey’s test for 
comparison of means. All analyses were per-
formed with a significance level of P<0.01. The 
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Figure 1. Urinary tract of the female Fischer 344 rats. Group 1 (A, I), Group 2 (B, C, J, K, L), Group 3 (D), Group 4 (E), 
Group 5 (F), Group 6 (G) and Group 7 (H). In (A), (E) and (H) the urinary tract showed normal features. (B and C) Le-
sions widespread in different regions of the urinary tract: hydronephrosis; nodular lesions in the kidneys (asterisks) 
in the kidneys; hydroureter (open arrowheads); renal atrophy (star); and thickening of the urinary bladder wall (solid 
arrowhead). (D and F) Lesions widespread in different regions of the urinary tract: nodular lesions in the kidneys 
(asterisks); renal atrophy (star); hydroureter (open arrowheads); and thickening of the urinary bladder wall (solid ar-
rowhead). (E and H) Areas of scarring (fibrosis) in the urinary bladder wall (solid arrowhead). (G) Discrete thickening 
of the ureters (hydroureter) (open arrowheads) and urinary bladder (solid arrowhead). (I) Frontal section through the 
left kidney: renal cortex (C), renal medulla (M) and renal pelvis (RP). (J) Nodular lesions (asterisks) evident on the 
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kidney external surface. (K) Frontal section through the right kidney demonstrating hydronephrosis and neoplastic 
papillary lesions (arrows) in the renal parenchyma. (l) Intravesical neoplastic papillary lesions (arrows) in the urinary 
bladder; urinary calculi (asterisks). (A-L) LK-left kidney, LU-left ureter, RK-right kidney, RU-right ureter, UB-urinary 
bladder.
Figure 2. Photomicrographs of the urinary bladder. Group 1 (A, B), Group 2 (C, D), Group 3 (E, F), Group 4 (G, H), 
Group 5 (I, J), Group 6 (K, L) and Group 7 (M, N, O). (A, B) and (M) Normal urothelium composed of 2-3 layers: a basal 
cell layer (solid arrowhead), an intermediate cell layer (arrow) and a superficial or apical layer composed of umbrella 
cells (open arrowhead). (C and D) Tumor invading mucosa or submucosa of the bladder wall (pT1): neoplastic cells 
arranged in small groups (arrows) invading the lamina propria; mitotic figures (solid arrowheads). (E, F, I and K) 
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results are expressed as the mean ± standard 
deviation.
Results
Histopathological analysis
The urinary tracts from Group 1 showed no 
macroscopic (Figure 1A, 1I) or microscopic 
changes (Figure 2A, 2B; Table 1). The normal 
urothelium was composed of 2-3 layers: a basal 
cell layer, an intermediate cell layer, and a 
superficial or apical layer composed of umbrel-
la cells (Figure 2A, 2B).
In contrast, the urinary tracts from Group 2 
showed deep macroscopic and histopathologi-
cal changes, including hydronephrosis, hydro-
ureter, thickening and papillary lesions in the 
urinary bladder, nodular lesions in the kidneys 
and renal atrophy (Figure 1B, 1C, 1J-L). Urinary 
bladders with tumor invading mucosa or sub-
mucosa of the bladder wall (pT1) and high-
grade papillary carcinoma in situ (pTa) were 
found in 80% and 20% of the animals, respec-
tively (Figure 2C, 2D; Table 1). In addition, kera-
tinizing squamous metaplasia was found in 
60% of the animals from Group 2.
Low-grade papillary carcinoma in situ (pTa) 
(80%) was the histopathological change most 
frequent in the urinary bladders from Group 3, 
and 20% of the animals in this group showed 
normal histology of the urinary bladder (Figure 
2E, 2F; Table 1). In addition, the urinary tracts 
from Group 3 showed macroscopic changes, 
including nodular lesions in the kidneys, hydro-
ureter, thickening and papillary lesions in the 
urinary bladder and renal atrophy (Figure 1D). 
The macroscopic features of the urinary tract 
from Group 4 were similar to those found in the 
Group 1 (Figure 1E). However, the urinary blad-
der wall showed areas of scarring (fibrosis) 
(Figure 1E). In the urinary bladder, normal uro-
thelium was found in 40% of the animals 
(Figure 2G; Table 1). Flat hyperplasia (40%) and 
low-grade papillary carcinoma in situ (pTa) 
(20%) were the most frequent histopathological 
changes in Group 4 (Figure 2H; Table 1). 
Low-grade papillary carcinoma in situ (60%), 
high-grade papillary carcinoma in situ (20%) 
and flat carcinoma in situ (pTis) (20%) were the 
most common histopathological changes in the 
urinary bladders from Group 5 (Figure 2I, 2J; 
Table 1). Keratinizing squamous metaplasia 
was found in 40% of the animals. In addition, 
the urinary tracts from Group 5 showed macro-
scopic changes, including hydronephrosis, 
hydroureter, thickening and papillary lesions in 
the urinary bladder and nodular lesions in the 
kidneys (Figure 1F). 
The incidence of macroscopic urinary tract 
lesions was significantly lower in Group 6 than 
in Group 3 and Group 5 (Figure 1G). The most 
Low-grade papillary carcinoma in situ (pTa) characterized by a fibrovascular stalk and frequent papillary branching, 
with increased cellular size. (G, H, L and N) Flat hyperplasia composed of several layers: a basal cell layer (solid 
arrowhead), intermediate cell layer (arrow), and a superficial or apical layer composed of umbrella cells (open arrow-
head). (J) Flat carcinoma in situ (pTis) characterized by cellular atypia: bulky nuclei (arrows) with reduced cytoplasm 
and prominent nucleoli. (O) Papillary hyperplasia characterized by a markedly thickened mucosa without cytological 
atypia. (A-O) Lp-lamina propria, M-muscular layer, Ur-urothelium.
Table 1. Percentage of histopathological changes in the urinary bladder of rats from experimental 
Groups
Histopatology Group 1 (n=5)
Group 2 
(n=5)
Group 3 
(n=5)
Group 4 
(n=5)
Group 5 
(n=5)
Group 6 
(n=5)
Group 7 
(n=5)
Normal 05 (100%) - 01 (20%) 02 (40%) - - 03 (60%)
Flat Hyperplasia - - - 02 (40%) - 02 (40%) 01 (20%)
Papillary Hyperplasia - - - - - - 01 (20%)
Flat carcinoma in situ (pTis) - - - - 01 (20%) 01 (20%) -
Low-grade Papillary Carcinoma in situ (pTa) - - 04 (80%) 01 (20%) 03 (60%) 02 (40%) -
High-grade  Papillary Carcinoma in situ (pTa) - 01 (20%) - - 01 (20%) - -
Tumor invading mucosa or submucosa of the bladder wall (pT1) - 04 (80%) - - - - -
Control group: Group 1, MNU group: Group 2, MNU-BCG group: Group 3, MNU-P-MAPA group: Group 4, MNU-Flutamide group: Group 5, MNU-BCG-Flutamide group: Group 
6 and MNU-P-MAPA-Flutamide group: Group 7.
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Figure 3. Immunolabelled of the uri-
nary bladder. Group 1 (A, H), Group 
2 (B, I), Group 3 (C, J), Group 4 (D, 
K), Group 5 (E, L), Group 6 (F, M) 
and Group 7 (G, N). (A-G) Siah-2 im-
munoreactivities (arrow) in the nu-
clei of urothelial cells. (H-N) N-CoR 
immunoreactivities (arrow) in the 
nuclei of urothelial cells. (A-N) Lp-
lamina propria, M-muscular layer, 
Ur-urothelium. 
common macroscopic changes in the urinary 
tracts from Group 6 were discrete thickening of 
the ureter (hydroureter) and urinary bladder 
(Figure 1G). Urinary bladders with low-grade 
papillary carcinoma in situ (pTa), flat carcinoma 
in situ (pTis) and flat hyperplasia were found in 
40%, 20% and 40% of the animals, respectively 
(Figure 2K, 2L; Table 1). 
Siah2 and N-CoR in non-muscle invasive bladder cancer
4435 Int J Clin Exp Pathol 2015;8(5):4427-4443
The macroscopic features of the urinary tract 
from the Group 7 were similar to those found in 
Group 1 and Group 4, showing only areas of 
scarring (fibrosis) in the urinary bladder wall 
Figure 4. Representative Western Blotting of AR, Siah-2, ERα, ERβ, N-CoR and CYP450 protein levels. Samples of 
urinary bladder were pooled from 5 animals per group for each repetition (duplicate) and used for semi-quantitative 
densitometry (IOD-Integrated Optical Density) analysis of the AR, Siah-2, ERα, ERβ, N-CoR and CYP450 levels fol-
lowing normalization to the β-actin. All data were expressed as the mean ± standard deviation. Different lowercase 
letters (A-D) indicate significant differences (P<0.01) between the groups after Tukey’s test.
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(Figure 1H). In the urinary bladder, normal uro-
thelium was found in 60% of the animals (Figure 
2M; Table 1). The most often histopathological 
changes in the MNU-P-MAPA group were flat 
hyperplasia (20%) and papillary hyperplasia 
(20%) (Figure 2N, 2O; Table 1). 
Urinary calculi (Figure 1L) and macroscopic 
hematuria were only observed in Group 2, 
Group 3, Group 5 and Group 6 but were absent 
in Groups 4 and 7.
Immunodetection of Siah-2 and N-CoR and 
Western blotting analysis
The Siah-2 protein levels were significantly 
higher in Group 2 (0.86) and Group 3 (0.70) 
than in the other experimental groups, showing 
intense immunoreactivities in the nuclei of uro-
thelial cells (Figures 3B, 3C, 4; Table 2). In addi-
tion, these levels were significantly higher in 
Group 5 (0.61) than in Group 6 (0.30), Group 1 
(0.29), Group 7 (0.23) and Group 4 (0.26), 
which exhibiting moderate and weak immuno-
reactivities, respectively (Figures 3A, 3D-G, 4; 
Table 2). In contrast, the N-CoR protein levels 
were significantly higher in Group 4 (0.81), 
Group 7 (0.73), Group 6 (0.70) and Group 5 
(0.63) than in the other experimental groups, 
showing intense immunoreactivities in the 
nuclei of urothelial cells (Figures 3H-3N, 4; 
Table 2). 
The highest AR protein levels were found in 
Group 2 (1.22) and Group 3 (1.00) (Figure 4). 
Additionally, these levels were significantly 
higher in the Group 1 (0.56) in relation to Group 
4 (0.42), Group 5 (0.36), Group 6 (0.35) and 
Group 7 (0.30) (Figure 4). In contrast, ERα and 
ERβ protein levels were significantly higher in 
Group 4 (1.40; 0.99), Group 5 (1.50; 0.87), 
Group 6 (1.30; 0.82) and Group 7 (1.27; 0.94) 
than in the other experimental groups (Figure 
4) Additionally, these levels were significantly 
higher in the Group 1 (0.82; 1.20) in relation to 
Group 2 (0.30; 0.09) and Group 3 (0.63; 0.70) 
(Figure 4). 
The highest CYP450 protein levels were found 
in Group 4 (0.31), Group 6 (0.35) and Group 7 
(0.31) (Figure 4). Additionally, these levels were 
significantly higher in Group 3 (0.19) than in 
Group 1 (0.12) and Group 2 (0.04) (Figure 4).
The highest TLR4 protein levels were found in 
Group 7 (1.53) and Group 4 (1.30), which were 
higher than in Group 6 (1.02) (Figure 5). 
Additionally, these levels were significantly 
higher in Group 3 (0.93), Group 5 (0.86) and 
Group 1 (0.85) than in Group 2 (0.57) (Figure 
5).
The TRIF and IRF3 protein levels were signifi-
cantly higher in Group 7 (3.04; 0.80) and Group 
4 (2.04; 0.69) than in Group 3 (1.90; 0.23) and 
Group 6 (1.57; 0.21) (Figure 5). In addition, 
these levels were significantly higher in Group 1 
(1.18; 0.15) and Group 5 (0.88; 0.12) than in 
Group 2 (0.59; 0.08) (Figure 5).
The IFN-γ protein levels were significantly high-
er in Group 7 (3.14) and Group 4 (2.41) than in 
Groups 3 (1.27) and 6 (1.16) (Figure 5). In addi-
tion, these levels were significantly higher in 
Group 2 (1.00) than in Group 1 (0.75) and 
Group 5 (0.68) (Figure 5).
The highest TLR2 protein levels were found in 
Group 4 (1.50) and Group 7 (1.37) (Figure 6). 
Furthermore, these levels were significantly 
higher in Group 3 (1.16) and Group 6 (1.02) 
than in Groups 5 (0.82), 1 (0.77) and 2 (0.77) 
(Figure 6). 
Table 2. Immunolabelled antigens intensity of the urinary bladder of rats in the different experimental 
groups
Groups
Antigens Group 1 (n=5)
Group 2 
(n=5)
Group 3 
(n=5)
Group 4 
(n=5)
Group 5 
(n=5)
Group 6 
(n=5)
Group 7 
(n=5)
Siah-2 1 (5.4%) 3 (86.7%) 3 (77.8%) 1 (18.3%) 2 (55.0%) 1 (27.3%) 1 (14.9%)
N-CoR 3 (81.3%) 1 (20.7%) 1 (18.9%) 3 (78.6%) 3 (76.1%) 3 (93.7%) 3 (90.0%)
Control group: Group 1, MNU group: Group 2, MNU-BCG group: Group 3, MNU-P-MAPA group: Group 4, MNU-Flutamide group: 
Group 5, MNU-BCG-Flutamide group: Group 6 and MNU-P-MAPA-Flutamide group: Group 7. Staining intensity grade: 0 (no im-
munoreactivity), 0% positive urothelial cells; 1(weak immunoreactivity), 1-35% positive urothelial cells; 2 (moderate immunore-
activity), 36-70% positive urothelial cells; 3 (intense immunoreactivity), >70% positive urothelial cells.
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The MyD88 protein levels were significantly 
higher in Group 3 (2.28) and Group 4 (2.24) 
than in Groups 1 (1.91), 6 (1.74), 7 (1.72), 2 
(1.30) and 5 (1.11) (Figure 6). 
The highest NF-kB protein levels were found in 
Group 3 (2.70) in relation to Group 6 (1.90) 
(Figure 6). In addition, these levels were signifi-
cantly higher in Group 2 (1.40) than in Group 4 
(0.90), Group 5 (0.81), Group 1 (0.70) and 
Group 7 (0.40) (Figure 6).
The TNF-α protein levels were significantly high-
er in Group 1 (1.12), Group 4 (1.06) and Group 
3 (1.00) than in Groups 6 (0.75), 5 (0.35), 2 
(0.31) and 7 (0.28) (Figure 6). 
Discussion
Steroid hormone receptors are involved in the 
development and progression of bladder can-
cer (BC). The AR and ERα/ERβ expression has 
been evaluated in BC and showed contradicto-
ry effects in relation to the histopathological 
characteristics of the tumors [13, 28-30].
Our results demonstrated deep macroscopic 
and histopathological changes in the MNU 
group, including hydronephrosis, hydroureter, 
nodular lesions in the kidneys, tumor invading 
mucosa or submucosa of the bladder wall (pT1) 
and keratinizing squamous metaplasia. The 
combined treatment with BCG and flutamide 
Figure 5. Representative Western Blotting of TLR4, TRIF, IRF3 and IFN-γ protein levels. Samples of urinary bladder 
were pooled from 5 animals per group for each repetition (duplicate) and used for semi-quantitative densitometry 
(IOD-Integrated Optical Density) analysis of the TLR4, TRIF, IRF3 and IFN-γ levels following normalization to the 
β-actin. All data were expressed as the mean ± standard deviation. Different lowercase letters (A-D) indicate signifi-
cant differences (P<0.01) between the groups after Tukey’s test.
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was more effective than either therapy alone 
and resulted in benign lesions (flat hyperpla-
sia), low-grade pTa and pTis. However, P-MAPA 
immunotherapy showed better histological 
recovery than did BCG and BCG with flutamide 
treatments; 40% of the animals showed com-
plete recovery of neoplasic lesions, 40% had 
benign lesions (flat hyperplasia) and 20% had 
low-grade pTa; therefore, 80% of the animals 
were tumor-free. In this study, the best histo-
pathological recovery resulted from the com-
bined treatment with P-MAPA and flutamide, 
which led to complete recovery of neoplastic 
lesions in 60% of the animals and benign 
lesions (flat and papillary hyperplasia) in 40% of 
the animals; therefore, 100% of the animals 
were tumor-free.
In regards to steroid hormone receptor protein 
levels, the highest AR protein levels were found 
in the MNU and BCG groups, whereas the level 
was significant lower in the groups that received 
flutamide. Interestingly, P-MAPA immunothera-
py was able to reduce AR protein levels inde-
pendently of flutamide. In contrast, the ERα 
and ERβ protein levels were significantly higher 
in the P-MAPA group and in the groups that 
received flutamide. Similarly, P-MAPA immuno-
therapy was able to increase the ERα and ERβ 
protein levels independently of flutamide.
The outstanding reduction in AR protein levels, 
accompanied by the proportional reduction in 
ERα and ERβ levels, in the animals treated with 
flutamide was previously described in other 
Figure 6. Representative Western Blotting of TLR2, MyD88, NF-kB and TNF-α protein levels. Samples of urinary blad-
der were pooled from 5 animals per group for each repetition (duplicate) and used for semi-quantitative densitom-
etry (IOD-Integrated Optical Density) analysis of the TLR2, MyD88, NF-kB and TNF-α levels following normalization 
to the β-actin. All data were expressed as the mean ± standard deviation. Different lowercase letters (A-D) indicate 
significant differences (P<0.01) between the groups after Tukey’s test.
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studies that used the same antagonist for AR 
[28-30]. In rodents, stimulatory and inhibitory 
effects of estrogen signaling were observed in 
both in vitro and in vivo experiments [28, 29], 
including the selective modulation of ERs in 
urothelial cell carcinoma growth via ERα and 
ERβ that may be directly or indirectly under the 
influence of AR [30]. Several studies detected 
positive AR expression in 52-100% of bladder 
cancer samples [30, 31]. In these studies, AR 
levels showed no significant difference in both 
men and women tumors. Miyamoto et al. [13] 
and other authors [30, 32] analyzed superficial 
bladder tumors using qRT-PCR and demon-
strated that several urothelial cell carcinoma 
were AR-positive, and high AR-expressing 
tumors tended to have a higher risk of recur-
rence than those with low AR-expressing 
tumors.
Several studies have shown reduced estrogen 
receptor expression (12-33%) in bladder can-
cer samples [30, 33]. ERα expression has been 
shown to be decreased in BC [34]. Miyamoto et 
al. [30] showed that ERβ expression was posi-
tive in 49.0% of bladder tumor samples in rela-
tion to benign urothelium, which was signifi-
cantly lower. Also, Kontos et al. [7] demonstrat-
ed that ERβ expression levels were significantly 
higher in normal urothelium in relation to malig-
nant urothelium.
Thus, it could be concluded that the different 
steroid hormone receptor protein levels in the 
NMIBC result in different signals to the dynam-
ics of the urinary bladder, and the importance 
of AR signals in the growth and progression of 
NMIBC is also clear. Furthermore, ERα and ERβ 
were fundamental in maintaining the structure 
of the benign urothelium. Here, we present a 
new therapeutic approach for bladder cancer 
based on anti-androgen therapy with flutamide 
and immunotherapy with P-MAPA and/or BCG. 
The combined treatment with P-MAPA and flu-
tamide showed a better recovery of bladder his-
tology features and ERα/ERβ protein levels 
than observed in the BCG and BCG with flu-
tamide treatment groups. 
In general, the interactions between co-activa-
tors and co-repressors (also named as co-regu-
lators) are responsible by control of AR activity 
[35]. These co-regulators can induce altera-
tions in chromatin structure through posttrans-
lational modifications of the core histone ami-
no-termini [36]. Corepressor N-CoR, a high 
molecular multiprotein complex, is related with 
the modulation of HDAC3 (histone deacetylase) 
enzymatic activity [36]. Kontos et al. [7] showed 
that expression of both ERβ and its co-repres-
sor N-CoR were inhibited in urothelial cells car-
cinoma. Atltintas et al. [37] demonstrated that 
after androgen stimulation, AR target genes 
were expressed in the G1 phase of the cell 
cycle in prostate cells, and that AR overexpres-
sion inhibited N-CoR activity leading to stimula-
tion AR-dependent expression of genes. These 
same authors showed that cell cycle-depen-
dent expression of N-CoR is responsible of the 
non-productive binding of AR to the promoter of 
target genes during the S and G2-M phases, 
since N-CoR is expressed only during these 
phases. Interestingly, AR targeting occurs at 
chromatin sites at which AR is bound to the 
transcriptional corepressor N-CoR [16].
The selective degradation of repressed AR 
complexes results in their replacement with AR 
bound to co-activators, resulting in up-regula-
tion of AR- and Siah2-dependent genes [16]. 
Studies have demonstrated that Siah-2 acts as 
an E3 ubiquitin ligase for the AR, repressing AR 
chromatin complex for degradation and activat-
ing several AR-regulated cellular processes 
such as tumor cell proliferation, cell motility 
and lipid metabolism [14]. Under low androgen 
concentration, Siah-2 activity is required for 
prostate cancer cells growth, whereas castra-
tion therapy leads to inhibition of Siah-2 activi-
ty, resulting in tumor growth suppression [14, 
16]. Experimental studies have also shown that 
the relation between Siah-2 and AR is involved 
in characteristic malignant behaviors such as 
anchorage-independent growth, cell motility 
and growth of castration-resistant prostate 
tumors [14, 39]. Thus, these results demon-
strated a new mechanism of AR regulation in 
the carcinogenesis, based on Siah-2 targeting 
[14]. Qi et al. [16] verified that knockout of Siah-
2 in the TRAMP transgenic mouse model of 
prostate cancer led to decreased prostate size 
and suppression of tumor formation. In addi-
tion, the same authors showed that regulation 
of AR transcriptional activity by Siah2 was 
important for castration-resistant prostate can-
cer development.
In the present study, we demonstrate the con-
trol of AR, ERα and ERβ activity by the Siah-2 
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ubiquitin ligase and the co-repressor N-CoR in 
NMIBC. Our results show that the Siah-2 pro-
tein levels were significantly higher in the MNU 
and BCG groups. Treatment with flutamide 
alone and/or in association with BCG reduced 
these protein levels. However, treatment with 
P-MAPA alone and/or in association with flu-
tamide showed the smallest reduction in the 
Siah-2 protein levels. In contrast, increased 
N-CoR protein levels were verified in the groups 
that received flutamide in association with 
P-MAPA and/or BCG. However, the P-MAPA 
treatment was able to increase N-CoR protein 
levels independently of flutamide. Thus, it can 
be concluded that P-MAPA immunotherapy 
downregulates Siah-2 protein levels and upreg-
ulates N-CoR levels, which were correlated with 
decreased AR protein levels and increased 
expression of estrogen receptors. These results 
demonstrated that the control of Siah-2 and 
N-CoR activities by P-MAPA were essential for 
histopathological recovery from the cancer 
state.
The activation of immune system receptors 
(e.g., TLRs) may represent a new therapeutic 
strategy for cancer control. Many studies 
showed that the use of TLRs agonists led to an 
important antitumor effect in vivo and sup-
pressed the growth of urothelial cancer cell 
lines, in vitro [40-42]. Thus, TLR-based immu-
notherapies might also be successful for the 
treatment of NMIBC. TLRs expressions are sig-
nificantly higher in benign urothelial tissue in 
relation to tumor cells, although their expres-
sions persist in these cells at low levels, 
enabling the use of TLR agonists for cancer 
therapy [40-42]. BCG is the main immunothera-
py for NMIBC, acting as TLRs 2 and 4 agonists 
through its mycobacterial components [43]. 
Based on experimental findings that certain 
antigens present in the mycobacterial cell wall 
are recognized by macrophages and dendritic 
cells, a cellular immune response against the 
mycobacteria related with TLR signaling is 
pointed [43]. For instance, in the TLR signaling 
pathway the factor MyD88 is essential for 
induction of inflammatory response to M. tuber-
culosis [44]. Scanga et al. [44] demonstrated 
that M. tuberculosis infection was more sus-
ceptible in MyD88-deficient mice than mice 
controls. The Hu35E6E7 urothelial cell line 
expresses many TLRs in its surface and induc-
es expression of MyD88 factor in the presence 
of BCG lipoproteins [44]. Also, the susceptibility 
to M. tuberculosis has been associated with 
TLR2 polymorphisms [45]. In addition to TLR2, 
TLR4 is also involved in the response to myco-
bacteria [42, 46]. BCG immunotherapy induced 
the activation of ERK1/2 MAPK pathway and 
secretion of interleukin-8 via TLRs 2 and 4 sig-
naling on human epithelial cells in response to 
mycobacteria infection [42, 46].
We have demonstrated in the present study 
that BCG treatment increased TLR2 protein lev-
els, resulting in increased MyD88 and NF-kB 
protein levels. The induction of the MyD88-
dependent pathway by BCG treatment led to 
increased protein levels of inflammatory cyto-
kines (TNF-α). However, MyD88, NF-kB and 
TNF-α protein levels were reduced in the ani-
mals that received only flutamide treatment or 
flutamide in addition to BCG. Moreover, treat-
ment with P-MAPA increased TLR4 protein lev-
els, resulting in increased TRIF and IRF3 pro-
tein levels. The induction of the TRIF-dependent 
pathway by P-MAPA led to increased IFN-γ pro-
tein levels. Furthermore, TLR4, TRIF, IRF3 and 
IFN-γ protein levels were increased in the ani-
mals that received flutamide in addition to 
P-MAPA.
Earlier studies from our research group showed 
that P-MAPA significantly increased TLR2, TLR4 
and p53 protein levels in an NMIBC animal 
model, and these increases were correlated 
with cancer regression [27]. In addition, it was 
demonstrated that this immunomodulator was 
more effective for the treatment of NMIBC than 
was BCG [27]. Santiago et al. [47] investigated 
the immunotherapeutic potential of P-MAPA on 
canine visceral leishmaniasis and verified that 
in peripheral blood mononuclear cell cultures, 
supernatants showed a decrease in IL-10 levels 
and an increase in IL-2 and IFN-γ as well as an 
increase in CD8 T cells after P-MAPA 
treatment.
In accordance with our data, we conclude that 
P-MAPA immunotherapy led to distinct activa-
tion of the innate immune system through TLRs 
2 and 4 in relation to BCG, resulting in increased 
interferon signaling, which was more effective 
for the treatment of NMIBC. The flutamide 
treatment reduced the ability of BCG to induce 
the MyD88-dependent pathway and potentiat-
ed the P-MAPA induction of interferon produc-
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tion (TRIF-dependent pathway). In addition, the 
interferon signaling pathway was correlated to 
increase N-CoR and decreased Siah-2 protein 
levels, which affected the steroid hormone 
receptor signals in urinary bladder carcino- 
genesis. 
We demonstrated that cytochrome P450 
(CYP450) protein levels were significantly high-
er in the flutamide treatment co-administered 
with P-MAPA and/or BCG immunotherapies. 
However, only P-MAPA treatment was able to 
increase CYP450 protein levels independently 
of flutamide treatment.
CYP450 is involved in the synthesis and metab-
olism of sex steroid hormones, and this activity 
may play a major role in both the development 
and progression of certain cancers, such as 
those of the breasts and prostate [48]. In addi-
tion, CYP in the rat bladder may also be regu-
lated by growth hormone as well as by andro-
gens. CYPs activities are related to metabolism 
of carcinogens, as well as in the modulation of 
tumors response to chemotherapeutic agents 
[49]. Furthermore, elevated expression of sev-
eral CYP family members were verified in 
tumors relative to normal human tissues, and, 
therefore, these CYPs could be considered as 
molecular targets for the cancer treatment 
[50]. In this regard, a potential approach for 
bladder cancer is to use the oxidation function-
ality of CYP1A1 to restore the potential toxicity 
to an inactivated chemotherapeutic selectively 
within the tumor, thereby facilitating reduced 
systemic toxicity and improving the therapeutic 
index [50].
In the present study, the decreased AR protein 
levels and the action of P-MAPA immunothera-
py might have contributed to the increased CYP 
protein levels and therefore favored stimulation 
of the innate immune system, especially elicit-
ing an increased production of IFN-γ.
In conclusion, our results demonstrated that 
increased Siah-2 and AR protein levels and 
decreased N-CoR, CYP450 and estrogen recep-
tors levels played a critical role in the urothelial 
carcinogenesis, probably leading to escape of 
urothelial cancer cells from immune system 
attack. P-MAPA immunotherapy led to distinct 
activation of innate immune system TLRs 2 and 
4-mediated, resulting in increase of interferon 
signaling pathway, which was more effective at 
recovering the immunosuppressive tumor 
immune microenvironment and at recovering 
the bladder histology features than BCG treat-
ments. The AR blockade therapy was important 
in the modulating of downstream molecules of 
TLR2 and TLR4 signaling pathway, decreasing 
the inflammatory cytokines signaling and 
enhancing the interferon signaling pathway 
when associated with P-MAPA. Taken together, 
the data obtained suggest that interferon sig-
naling pathway activation and targeting AR and 
Siah-2 signals by P-MAPA intravesical immuno-
therapy alone and/or in combination with AR 
blockade may provide novel therapeutic 
approaches for NMIBC.
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